Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion
Our team put this together to quickly summarize the key distinctions for researchers trying to decide which compound is appropriate for their work
Secondary efficacy measures further support the treatments benefits
B12 effects may last up to 12 weeks
For the full analysisinclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citationsyou can view the complete report on MedRxiv or directly within Truveta Studio
US$ 26.17
US$ 22.76
US$ 26.42
US$ 24.76
